Radiofrequency thermal ablation of metastatic neuroendocrine tumors in the liver

被引：13
作者：
Mazzaglia P.J. [1 ]
Berber E. [1 ]
Siperstein A.E. [1 ]
机构：
[1] Department of Surgery A-80, Cleveland Clinic Foundation, Cleveland, OH
来源：
Current Treatment Options in Oncology | 2007年 / 8卷 / 4期
关键词：
Octreotide; Endocrine Tumor; Lanreotide; Medullary Thyroid Cancer; Carcinoid Syndrome;
D O I：
10.1007/s11864-007-0038-9
中图分类号：
学科分类号：
摘要：
In our armamentarium against neuroendocrine hepatic metastases, radiofrequency thermal ablation has proven to play a valuable role. Patients with neuroendocrine malignancies that progress to hepatic metastases may suffer not only from the hormonal sequelae of their disease, but also face the specter of death within several years from progressive hepatic replacement. For the majority of these patients who are not surgical candidates due to the extent of liver involvement, radiofrequency thermal ablation represents a low-risk treatment modality effective at both symptom alleviation and survival prolongation. Utilizing a laparoscopic approach guided by intra-operative ultrasound, effective tumor ablation can be achieved with minimal morbidity and low rates of local tumor recurrence. © Current Science Inc. 2007.
引用
收藏
页码：322 / 330
页数：8
相关论文
共 30 条
  • [11] Chamberlain R.S., Canes D., Brown K.T., Et al., Hepatic neuroendocrine metastases: Does intervention alter outcomes?, J Am Coll Surg, 190, 4, pp. 432-445, (2000)
  • [12] Nave H., Mossinger E., Feist H., Et al., Surgery as primary treatment in patients with liver metastases from carcinoid tumors: A retrospective, unicentric study over 13 years, Surgery, 129, 2, pp. 170-175, (2001)
  • [13] Que F.G., Nagorney D.M., Batts K.P., Et al., Hepatic resection for metastatic neuroendocrine carcinomas, Am J Surg, 169, 1, pp. 36-42, (1995)
  • [14] Carrasco C.H., Charnsangavej C., Ajani J., Et al., The carcinoid syndrome: Palliation by hepatic artery embolization, AJR Am J Roentgenol, 147, 1, pp. 149-154, (1986)
  • [15] Perry L.J., Stuart K., Stokes K.R., Clouse M.E., Hepatic arterial chemoembolization for metastatic neuroendocrine tumors, Surgery, 116, 6, pp. 1111-1116, (1994)
  • [16] Kvols L.K., Moertel C.G., O'Connell M.J., Et al., Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue, N Engl J Med, 315, 11, pp. 663-666, (1986)
  • [17] Janson E.T., Oberg K., Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon, Acta Oncol, 32, 2, pp. 225-229, (1993)
  • [18] Ruszniewski P., Ducreux M., Chayvialle J.A., Et al., Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: A prospective study in 39 patients, Gut, 39, 2, pp. 279-283, (1996)
  • [19] Bilchik A.J., Sarantou T., Foshag L.J., Et al., Cryosurgical palliation of metastatic neuroendocrine tumors resistant to conventional therapy, Surgery, 122, 6, pp. 1040-1047, (1997)
  • [20] Proye C.A., Lokey J.S., Current concepts in functioning endocrine tumors of the pancreas, World J Surg, 28, 12, pp. 1231-1238, (2004)
123